Holen Sie sich die Stockscreener-App
42.57
6.75%
-3.08
Handel nachbörslich:
42.78
0.21
+0.49%
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme CEO: Evotec Is Poised for Growth - Marketscreener.com
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery - MarketWatch
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme Bids €2B for Evotec, Eyes $2B Revenue by 2025 in Pharma Services Push | HALO Stock News - StockTitan
Royce & Associates LP Has $7.10 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme (HALO) Eyes $21 Billion Cash Acquisition of Evotec (EVO) - GuruFocus.com
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
The week in pharma: action, reaction and insight – week to November 15 - The Pharma Letter
Cornercap Investment Counsel Inc. Sells 20,204 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
South Street Advisors LLC Purchases New Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Mizuho Markets Americas LLC Trims Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - MSN
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec - MedCity News
Halozyme Therapeutics (NASDAQ:HALO) Shares Gap DownHere's What Happened - MarketBeat
Halozyme Bid For Evotec Does Not Look High Enough - Scrip
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
Halozyme keeps Neutral rating, price target set on acquisition interest By Investing.com - Investing.com UK
Halozyme offers €11 per share to acquire Evotec for €2bn - World Pharmaceutical Frontiers
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Halozyme sets out offer to acquire Evotec - The Pharma Letter
Evotec spikes on buyout proposal from Halozyme - FirstWord Pharma
Halozyme offers $2B for Evotec to expand beyond tech used by J&J - Fierce Biotech
US competitor Halozyme offers two billion euros for Evotec - Marketscreener.com
Halozyme bids for Evotec; BeiGene gets a new name - Yahoo Finance
Evotec surges on Halozyme takeover interest - ShareCast
Market news - Research the market
Germany’s Evotec Gets Takeover Interest From Halozyme - Yahoo Finance
Halozyme (HALO) Aims for Global Innovation through Evotec Purchase - Value the Markets
HALOZYME THERAPEUTICS INC : JP Morgan gives a Neutral rating - Marketscreener.com
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
Halozyme Therapeutics Bids to Acquire German Competitor Evotec - MarketWatch
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports - MSN
Halozyme makes 2 billion euro buyout offer for drug developer Evotec - Reuters
Halozyme Bids €2B to Acquire Evotec, Offers 109% Premium in Major Biotech Deal | HALO Stock News - StockTitan
HALO Stock Dips 5.77% Amid Biotech Sector Changes - GuruFocus.com
Evotec jumps as Halozyme confirms takeover interest (updated) - Seeking Alpha
Halozyme interested in acquiring Evotec for $2.1B, Bloomberg says - TipRanks
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Future Fund LLC - MarketBeat
Principal Financial Group Inc. Trims Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Janney Montgomery Scott LLC - MarketBeat
Artisan Partners Limited Partnership Adjusts Stake in Halozyme T - GuruFocus.com
How the (HALO) price action is used to our Advantage - Stock Traders Daily
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Lessened by WCM Investment Management LLC - MarketBeat
Assetmark Inc. Has $5.33 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Needle Free Injectors Market Is Expected To Reach a Revenue Of USD 2,980.9 Million By 2033, At 8.1% CAGR: Dimension Market Research - GlobeNewswire Inc.
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - MSN
Foster & Motley Inc. Makes New $609,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Kornitzer Capital Management Inc. KS - MarketBeat
Hanseatic Management Services Inc. Invests $581,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme: Looking For More Growth Following Record Q3 Earnings (NASDAQ:HALO) - Seeking Alpha
Catalyst Capital Advisors LLC Invests $1.94 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme stock price target, rating held on earnings beat By Investing.com - Investing.com Canada
H.C. Wainwright lifts Halozyme stock target, buy rating on strong earnings - Investing.com Canada
Halozyme Therapeutics (NASDAQ:HALO) Given New $52.00 Price Target at Piper Sandler - MarketBeat
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Assenagon Asset Management S.A. Sells 40,070 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):